Transformed Non-hodgkin Lymphoma

• CLINICAL_TRIALS trial_result · 2026-04-22
  Clinical Trial Update: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment [Phase 1]

  Phase 1 trial to assess the safety of the anti-cancer drugs tazemetostat and belinostat in patients with recurrent or refractory lymphomas; …

• CLINICAL_TRIALS trial_result · 2024-02-01
  Clinical Trial Update: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. [Phase 1]

  Phase 1 study of pembrolizumab plus vorinostat in relapsed or refractory B-cell lymphomas and classic Hodgkin lymphoma; results posted in Fe…

• CLINICAL_TRIALS trial_result · 2022-09-13
  Clinical Trial Update: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL [Phase 2]

  Phase 2 study of AT13387 (Onalespib) in ALK+ anaplastic large cell lymphoma, mantle cell lymphoma, and BCL-6+ diffuse large B-cell lymphoma …

• CLINICAL_TRIALS trial_result · 2019-11-08
  Clinical Trial Update: Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A combined Phase 1/2 trial evaluating lenalidomide after chemotherapy and stem cell transplant in various forms of recurrent or resistant no…

• CLINICAL_TRIALS trial_result · 2012-04-23
  Clinical Trial Update: A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma [Phase 1]

  A Phase 1 study evaluating pharmacokinetics, whole-body/organ dosimetry, and biodistribution of fission-derived iodine-131 tositumomab (BEXX…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.